JP2009544756A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009544756A5 JP2009544756A5 JP2009522952A JP2009522952A JP2009544756A5 JP 2009544756 A5 JP2009544756 A5 JP 2009544756A5 JP 2009522952 A JP2009522952 A JP 2009522952A JP 2009522952 A JP2009522952 A JP 2009522952A JP 2009544756 A5 JP2009544756 A5 JP 2009544756A5
- Authority
- JP
- Japan
- Prior art keywords
- formula
- compound
- disease
- oxo
- salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 14
- 150000003839 salts Chemical class 0.000 claims 8
- 125000000217 alkyl group Chemical group 0.000 claims 6
- -1 6- (trifluoromethyl) quinazolin-4-ylamino Chemical group 0.000 claims 4
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 201000001320 Atherosclerosis Diseases 0.000 claims 3
- 208000011231 Crohn disease Diseases 0.000 claims 3
- PUJDIJCNWFYVJX-UHFFFAOYSA-N benzyl carbamate Chemical compound NC(=O)OCC1=CC=CC=C1 PUJDIJCNWFYVJX-UHFFFAOYSA-N 0.000 claims 3
- 239000013078 crystal Substances 0.000 claims 3
- 206010012601 diabetes mellitus Diseases 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 229910052739 hydrogen Inorganic materials 0.000 claims 3
- 239000001257 hydrogen Substances 0.000 claims 3
- 206010020718 hyperplasia Diseases 0.000 claims 3
- 201000006417 multiple sclerosis Diseases 0.000 claims 3
- 238000000634 powder X-ray diffraction Methods 0.000 claims 3
- 229940124597 therapeutic agent Drugs 0.000 claims 3
- 238000002054 transplantation Methods 0.000 claims 3
- 206010018364 Glomerulonephritis Diseases 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- 150000001732 carboxylic acid derivatives Chemical group 0.000 claims 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 2
- 230000003301 hydrolyzing effect Effects 0.000 claims 2
- 239000012948 isocyanate Substances 0.000 claims 2
- 150000002513 isocyanates Chemical class 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 210000000056 organ Anatomy 0.000 claims 2
- 208000037803 restenosis Diseases 0.000 claims 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 2
- 125000006318 tert-butyl amino group Chemical group [H]N(*)C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims 2
- LSROBYZLBGODRN-UHFFFAOYSA-N 1-aminopyrrolidin-2-one Chemical group NN1CCCC1=O LSROBYZLBGODRN-UHFFFAOYSA-N 0.000 claims 1
- 206010065040 AIDS dementia complex Diseases 0.000 claims 1
- 206010001889 Alveolitis Diseases 0.000 claims 1
- 206010002329 Aneurysm Diseases 0.000 claims 1
- 206010003210 Arteriosclerosis Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims 1
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 239000005973 Carvone Substances 0.000 claims 1
- 208000031886 HIV Infections Diseases 0.000 claims 1
- 208000037357 HIV infectious disease Diseases 0.000 claims 1
- 206010019196 Head injury Diseases 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 206010048858 Ischaemic cardiomyopathy Diseases 0.000 claims 1
- 239000002841 Lewis acid Substances 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010037660 Pyrexia Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 206010047115 Vasculitis Diseases 0.000 claims 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 1
- 150000008065 acid anhydrides Chemical class 0.000 claims 1
- 239000003377 acid catalyst Substances 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 150000001408 amides Chemical class 0.000 claims 1
- 125000006242 amine protecting group Chemical group 0.000 claims 1
- 150000001412 amines Chemical class 0.000 claims 1
- 239000000010 aprotic solvent Substances 0.000 claims 1
- 208000011775 arteriosclerosis disease Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000003638 chemical reducing agent Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 206010009887 colitis Diseases 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 150000002148 esters Chemical group 0.000 claims 1
- 201000001155 extrinsic allergic alveolitis Diseases 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 1
- 208000022098 hypersensitivity pneumonitis Diseases 0.000 claims 1
- 238000011065 in-situ storage Methods 0.000 claims 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 150000007517 lewis acids Chemical class 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 230000003589 nefrotoxic effect Effects 0.000 claims 1
- 201000008383 nephritis Diseases 0.000 claims 1
- 231100000381 nephrotoxic Toxicity 0.000 claims 1
- 208000004296 neuralgia Diseases 0.000 claims 1
- 208000021722 neuropathic pain Diseases 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 238000006268 reductive amination reaction Methods 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 0 CCC*C(CCC1N(CC[C@@]2*)C2=O)(C[C@]1N=C=O)O*CC* Chemical compound CCC*C(CCC1N(CC[C@@]2*)C2=O)(C[C@]1N=C=O)O*CC* 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US83423506P | 2006-07-28 | 2006-07-28 | |
| US60/834,235 | 2006-07-28 | ||
| US89602607P | 2007-03-21 | 2007-03-21 | |
| US60/896,026 | 2007-03-21 | ||
| US11/782,742 US7629351B2 (en) | 2006-07-28 | 2007-07-25 | N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-2-oxo-3-(6-(trifluoromethyl)quinazolin-4-ylamino) pyrrolidin-1-yl)cyclohexyl)acetamide and other modulators of chemokine receptor activity, crystalline forms and process |
| US11/782,742 | 2007-07-25 | ||
| PCT/US2007/074377 WO2008014360A2 (en) | 2006-07-28 | 2007-07-26 | Modulators of chemokine receptor activity, crystalline forms and process |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009544756A JP2009544756A (ja) | 2009-12-17 |
| JP2009544756A5 true JP2009544756A5 (enExample) | 2010-08-12 |
| JP5236643B2 JP5236643B2 (ja) | 2013-07-17 |
Family
ID=38829183
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009522952A Expired - Fee Related JP5236643B2 (ja) | 2006-07-28 | 2007-07-26 | ケモカイン受容体活性のモジュレーター、結晶形および方法 |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US7629351B2 (enExample) |
| EP (2) | EP2046779B1 (enExample) |
| JP (1) | JP5236643B2 (enExample) |
| KR (1) | KR20090033915A (enExample) |
| CN (1) | CN101535301B (enExample) |
| AR (1) | AR062124A1 (enExample) |
| AT (2) | ATE509926T1 (enExample) |
| AU (1) | AU2007279333B2 (enExample) |
| BR (1) | BRPI0715415A2 (enExample) |
| CA (2) | CA2831219A1 (enExample) |
| CY (1) | CY1111744T1 (enExample) |
| DK (1) | DK2046779T3 (enExample) |
| EA (1) | EA016563B1 (enExample) |
| ES (1) | ES2365264T3 (enExample) |
| HR (1) | HRP20110465T1 (enExample) |
| IL (2) | IL196427A (enExample) |
| MX (1) | MX2009000808A (enExample) |
| NO (1) | NO20090190L (enExample) |
| NZ (1) | NZ574425A (enExample) |
| PE (1) | PE20080732A1 (enExample) |
| PL (1) | PL2046779T3 (enExample) |
| PT (1) | PT2046779E (enExample) |
| SG (1) | SG158924A1 (enExample) |
| SI (1) | SI2046779T1 (enExample) |
| TW (2) | TWI421249B (enExample) |
| WO (1) | WO2008014360A2 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7687508B2 (en) * | 2006-07-28 | 2010-03-30 | Bristol-Myers Squibb Company | Cyclic derivatives as modulators of chemokine receptor activity |
| US8383812B2 (en) | 2009-10-13 | 2013-02-26 | Bristol-Myers Squibb Company | N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-3-(7-tert-butylpyrazolo[1,5-A][1,3,5]triazin-4-ylamino)-2-oxopyrrolidin-1-yl)cyclohexyl)acetamide, a dual modulator of chemokine receptor activity, crystalline forms and processes |
| KR20120135716A (ko) * | 2011-06-07 | 2012-12-17 | 한미사이언스 주식회사 | 이중대칭 구조의 퀴나졸린 유도체 화합물 및 이의 용도 |
| EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| US8669281B1 (en) | 2013-03-14 | 2014-03-11 | Alkermes Pharma Ireland Limited | Prodrugs of fumarates and their use in treating various diseases |
| MA40320A (fr) * | 2014-07-17 | 2017-05-24 | Santen Pharmaceutical Co Ltd | Agent prophylactique ou thérapeutique pour des troubles du segment postérieur de l'œil |
| HUE058049T2 (hu) | 2017-07-20 | 2022-06-28 | Bristol Myers Squibb Co | Eljárás N-((1R,2S,SR)-5-(terc-butilamino)-2-((S)-3-(7-terc-butilpirazolo[1,5-A][1,3,5] triazin-4-ilamino)-2-oxopirrolidin-1-il)ciklohexil)acetamid elõállítására |
| CN115677728A (zh) * | 2022-11-02 | 2023-02-03 | 成都科岭源医药技术有限公司 | 一种海鞘素类化合物中间体的制备方法 |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6383082A (ja) | 1986-09-26 | 1988-04-13 | Takeda Chem Ind Ltd | テトラヒドロフランカルボン酸誘導体の製造法 |
| EP0550924A1 (en) | 1991-12-16 | 1993-07-14 | Merck & Co. Inc. | 2-Pyrrolidinone derivatives as HIV protease inhibitors |
| GB9515411D0 (en) | 1995-07-27 | 1995-09-27 | Pharmacia Spa | N-(4-substituted-benzyl)-2-aminolactam derivatives |
| US5827875A (en) | 1996-05-10 | 1998-10-27 | Bristol-Myers Squibb Company | Inhibitors of microsomal triglyceride transfer protein and method |
| UA51716C2 (uk) | 1996-07-08 | 2002-12-16 | Авентіс Фармасьютікалз Продактс Інк. | Сполуки, що мають гіпотензивну, кардіопротекторну, анти-ішемічну та антиліполітичну властивості, фармацевтична композиція та способи лікування |
| US6054579A (en) | 1997-06-26 | 2000-04-25 | Leukosite, Inc. | Synthesis of substituted lactams |
| GB9716656D0 (en) | 1997-08-07 | 1997-10-15 | Zeneca Ltd | Chemical compounds |
| UA59433C2 (uk) | 1998-01-27 | 2003-09-15 | Авентіс Фармасьютікалс Продактс Інк. | ЗАМІЩЕНІ ОКСОАЗАГЕТЕРОЦИКЛІЧНІ ІНГІБІТОРИ ФАКТОРА Хa ТА ПРОМІЖНІ СПОЛУКИ ДЛЯ ЇХ ОТРИМАННЯ |
| AU747987B2 (en) | 1998-01-29 | 2002-05-30 | Aventis Pharmaceuticals Inc. | Method for preparing an N-((aliphatic or aromatic)carbonyl)-2-aminoacetamide compound and a cyclyzed compound |
| US6492553B1 (en) | 1998-01-29 | 2002-12-10 | Aventis Pharamaceuticals Inc. | Methods for preparing N-[(aliphatic or aromatic)carbonyl)]-2-aminoaetamide compounds and for cyclizing such compounds |
| GB9803228D0 (en) | 1998-02-17 | 1998-04-08 | Zeneca Ltd | Chemical compounds |
| US6541208B1 (en) | 1998-03-17 | 2003-04-01 | University Of Maryland Biotechnology Institute | Diagnostic method for distinguishing HIV-associated dementia from other forms of dementia |
| WO2001017992A1 (en) | 1999-09-09 | 2001-03-15 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
| US6620823B2 (en) | 2000-07-11 | 2003-09-16 | Bristol-Myers Squibb Pharme Company | Lactam metalloprotease inhibitors |
| AU2002241724A1 (en) * | 2000-12-20 | 2002-07-01 | Bristol-Myers Squibb Company | Diamines as modulators of chemokine receptor activity |
| WO2002060859A2 (en) | 2000-12-20 | 2002-08-08 | Bristol-Myers Squibb Company | Cyclic derivatives as modulators of chemokine receptor activity |
| EP1373494B1 (en) | 2001-03-29 | 2006-03-01 | Topo Target A/S | Succinimide and maleimide derivatives and their use as topoisomerase ii catalytic inhibitors |
| GB0114867D0 (en) | 2001-06-18 | 2001-08-08 | Merck Sharp & Dohme | Therapeutic agents |
| DE10135043A1 (de) * | 2001-07-11 | 2003-01-30 | Bayer Cropscience Gmbh | Substituierte 3-Heteroaryl(amino- oder oxy)-pyrrolidin-2-one, Verfahren zu deren Herstellung und Verwendung als Herbizide oder als Pflanzenwachstumsregulatoren |
| WO2003075853A2 (en) | 2002-03-08 | 2003-09-18 | Bristol-Myers Squibb Company | Cyclic derivatives as modulators of chemokine receptor activity |
| TW200307667A (en) * | 2002-05-06 | 2003-12-16 | Bristol Myers Squibb Co | Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors |
| WO2004022536A1 (en) | 2002-09-04 | 2004-03-18 | Glenmark Pharmaceuticals Limited | New heterocyclic amide compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them |
| US6835841B2 (en) | 2002-09-13 | 2004-12-28 | Bristol-Myers Squibb Company | Asymmetric catalytic hydrogenation process for preparation of chiral cyclic β-aminoesters |
| TW200508224A (en) * | 2003-02-12 | 2005-03-01 | Bristol Myers Squibb Co | Cyclic derivatives as modulators of chemokine receptor activity |
| WO2004071449A2 (en) * | 2003-02-12 | 2004-08-26 | Bristol-Myers Squibb Company | Lactams as modulators of chemokine receptor activity |
| US7291615B2 (en) * | 2003-05-01 | 2007-11-06 | Bristol-Myers Squibb Company | Cyclic derivatives as modulators of chemokine receptor activity |
| US7230133B2 (en) * | 2003-05-01 | 2007-06-12 | Bristol-Myers Squibb Company | Malonamides and malonamide derivatives as modulators of chemokine receptor activity |
| US20060205761A1 (en) | 2003-06-06 | 2006-09-14 | Catherine Abbadie | Ccr-2 antagonists for treatment of neuropathic pain |
| US7351720B2 (en) | 2003-06-12 | 2008-04-01 | Bristol-Myers Squibb Company | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity |
| US7317019B2 (en) * | 2003-08-21 | 2008-01-08 | Bristol Myers Squibb Co. | N-alkylated diaminopropane derivatives as modulators of chemokine receptor activity |
| US7163937B2 (en) * | 2003-08-21 | 2007-01-16 | Bristol-Myers Squibb Company | Cyclic derivatives as modulators of chemokine receptor activity |
| US7378409B2 (en) * | 2003-08-21 | 2008-05-27 | Bristol-Myers Squibb Company | Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity |
| US20050043392A1 (en) * | 2003-08-21 | 2005-02-24 | Carter Percy H. | Lactams of alkylated acyclic diamine derivatives as modulators of chemokine receptor activity |
| US7863317B2 (en) * | 2003-08-21 | 2011-01-04 | Bristol-Myers Squibb Company | Lactams of alkylated acyclic diamine derivatives as modulators of chemokine receptor activity |
| TWI354664B (en) * | 2003-08-21 | 2011-12-21 | Bristol Myers Squibb Co | Cyclic derivatives as modulators of chemokine rece |
| BRPI0513953A (pt) | 2004-07-30 | 2008-05-20 | Pfizer Prod Inc | métodos para tratamento de doenças ou distúrbios mediados pela ccr2 |
| WO2006036527A1 (en) * | 2004-09-28 | 2006-04-06 | Janssen Pharmaceutica, N.V. | Substituted dipiperdine ccr2 antagonists |
| US7687508B2 (en) * | 2006-07-28 | 2010-03-30 | Bristol-Myers Squibb Company | Cyclic derivatives as modulators of chemokine receptor activity |
-
2007
- 2007-07-25 US US11/782,742 patent/US7629351B2/en active Active
- 2007-07-26 EP EP07813363A patent/EP2046779B1/en active Active
- 2007-07-26 CA CA2831219A patent/CA2831219A1/en not_active Abandoned
- 2007-07-26 CN CN200780032859.9A patent/CN101535301B/zh not_active Expired - Fee Related
- 2007-07-26 KR KR1020097004311A patent/KR20090033915A/ko not_active Ceased
- 2007-07-26 AT AT07813363T patent/ATE509926T1/de active
- 2007-07-26 WO PCT/US2007/074377 patent/WO2008014360A2/en not_active Ceased
- 2007-07-26 PT PT07813363T patent/PT2046779E/pt unknown
- 2007-07-26 SG SG201000703-7A patent/SG158924A1/en unknown
- 2007-07-26 AU AU2007279333A patent/AU2007279333B2/en not_active Ceased
- 2007-07-26 BR BRPI0715415-1A patent/BRPI0715415A2/pt not_active IP Right Cessation
- 2007-07-26 ES ES07813363T patent/ES2365264T3/es active Active
- 2007-07-26 EA EA200900245A patent/EA016563B1/ru not_active IP Right Cessation
- 2007-07-26 DK DK07813363.4T patent/DK2046779T3/da active
- 2007-07-26 MX MX2009000808A patent/MX2009000808A/es active IP Right Grant
- 2007-07-26 PE PE2007000980A patent/PE20080732A1/es not_active Application Discontinuation
- 2007-07-26 EP EP10001989A patent/EP2194051B1/en not_active Not-in-force
- 2007-07-26 CA CA002659253A patent/CA2659253A1/en not_active Abandoned
- 2007-07-26 SI SI200730680T patent/SI2046779T1/sl unknown
- 2007-07-26 PL PL07813363T patent/PL2046779T3/pl unknown
- 2007-07-26 TW TW096127304A patent/TWI421249B/zh not_active IP Right Cessation
- 2007-07-26 TW TW102141345A patent/TW201414729A/zh unknown
- 2007-07-26 JP JP2009522952A patent/JP5236643B2/ja not_active Expired - Fee Related
- 2007-07-26 HR HR20110465T patent/HRP20110465T1/hr unknown
- 2007-07-26 NZ NZ574425A patent/NZ574425A/en not_active IP Right Cessation
- 2007-07-26 AT AT10001989T patent/ATE522522T1/de not_active IP Right Cessation
- 2007-07-27 AR ARP070103332A patent/AR062124A1/es not_active Application Discontinuation
-
2009
- 2009-01-11 IL IL196427A patent/IL196427A/en not_active IP Right Cessation
- 2009-01-13 NO NO20090190A patent/NO20090190L/no not_active Application Discontinuation
- 2009-10-27 US US12/606,255 patent/US8049019B2/en active Active
-
2010
- 2010-06-28 IL IL206679A patent/IL206679A0/en unknown
-
2011
- 2011-08-05 CY CY20111100753T patent/CY1111744T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009544756A5 (enExample) | ||
| JP5264830B2 (ja) | アミノクロトニル化合物の調製方法 | |
| JP2009544758A5 (enExample) | ||
| JP6240164B2 (ja) | ピロール誘導体の結晶及びその製造方法 | |
| WO1998022432A1 (en) | Novel acylamino-substituted acylanilide derivatives or pharmaceutical composition comprising the same | |
| CA2894016A1 (en) | Modulators of the retinoid-related orphan receptor gamma (ror-gamma) for use in the treatment of autoimmune and inflammatory diseases | |
| CN1227233C (zh) | 纯晶形的5－氯－3－(4－甲磺酰基苯基)－6′－甲基－[2,3′]联吡啶及其合成方法 | |
| JP6832946B2 (ja) | キナーゼ阻害剤およびその中間体の調製方法 | |
| KR102776189B1 (ko) | 발베나진의 고상 형태 | |
| JP2013532164A (ja) | トロンビン特異的インヒビターを調製する方法 | |
| JP2020534336A5 (enExample) | ||
| JP2012513381A5 (enExample) | ||
| IL235097A (en) | History of insulin-2 and as protein kinase inhibitors | |
| JP6297590B2 (ja) | １−（［１，３］ジオキソラン−４−イルメチル）−１ｈ−ピラゾール−３−イルアミンを調製するための方法 | |
| CN109476609B (zh) | 吡唑-酰胺化合物的制造方法 | |
| JP5047160B2 (ja) | ４−［［５−［（シクロプロピルアミノ）カルボニル］−２−メチルフェニル］アミノ］−５−メチル−Ｎ−プロピルピロロ［２，１−ｆ］［１，２，４］トリアジン−６−カルボキサミドの塩の製造法、および該製造法において製造される新規の安定なフォーム | |
| US10377712B2 (en) | Process for preparation of apremilast and novel polymorphs thereof | |
| JP2008544965A (ja) | ｐ３８キナーゼ阻害剤としての二環式誘導体 | |
| US20190144375A1 (en) | Novel carbocyclic compounds as ror gamma modulators | |
| KR101643285B1 (ko) | （하이드록시알킬）피롤 유도체의 회전장애이성질체 | |
| JP7406692B2 (ja) | 可溶性グアニル酸シクラーゼ刺激薬を調製するための方法 | |
| WO2017021904A1 (en) | Daclatasvir free base and process for the preparation thereof | |
| JP2008539181A (ja) | Ｅｐ１受容体アンタゴニストとして有用なフラン化合物 | |
| WO2025215672A1 (en) | "process for preparation of blarcamesine" | |
| JP2005532362A (ja) | インドール誘導スタチンのカルシウム塩 |